Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy

Documenti analoghi

• Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
  di: Furubayashi, Nobuki, et al.
  Pubblicazione: (2021)
• Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
  di: Furubayashi, Nobuki, et al.
  Pubblicazione: (2020)
• Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
  di: Furubayashi, Nobuki, et al.
  Pubblicazione: (2020)
• The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy
  di: Furubayashi, Nobuki, et al.
  Pubblicazione: (2017)
• Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
  di: Furubayashi N, et al.
  Pubblicazione: (2022-05-01)